John M. Timmerman

21.5k citations

108 papers · 5.6k indexed · 2 hit papers · h-index 26

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment

Papers in

Pathology and Forensic Medicine 69
- Lymphoma Diagnosis and Treatment 69
Oncology 88
- CAR-T cell therapy research 66
- Cancer Immunotherapy and Biomarkers 36

Co-authors: Stephen M. Ansell Philippe Armand Margaret A. Shipp Scott J. Rodig Alexander M. Lesokhin Li Zhu Azra H. Ligon Ivan Borrello
Journals: Blood (32 papers)Journal of Clinical Oncology (26 papers)Clinical Cancer Research (4 papers)Hematological Oncology (4 papers)Cancer Research (3 papers)
Partner nations: United States Canada Germany

In The Last Decade

John M. Timmerman

104 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial 2018 · 455 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2014 New England Journal of Medicine

Peers

Countries citing papers authored by John M. Timmerman

Since Specialization

Citations

This map shows the geographic impact of John M. Timmerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Timmerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Timmerman more than expected).

Fields of papers citing papers by John M. Timmerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Timmerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Timmerman. The network helps show where John M. Timmerman may publish in the future.

Co-authors

The 25 scholars most cited alongside John M. Timmerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John M. Timmerman Line = papers co-authored together John M. Timmerman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Transplantation and Cellular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Marie José Kersten, Yan Zheng, Teresa Zhang, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny Kim, David B. Miklos	2024	13
2	A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. Journal of Clinical Oncology ·John M. Timmerman, David Lavie, Borchmann Peter, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vučinić, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Nathalie A. Johnson	2024	2
3	Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR). Journal of Clinical Oncology ·Michael Maranzano, Angshuman Saha, John M. Timmerman, Patricia A. Young, Herbert Eradat, Sven de Vos, Sarah M. Larson, Monica Mead	2024	0
4	A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. Journal of Clinical Oncology ·John M. Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Borchmann Peter, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Torzan, Vladan Vučinić, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera	2024	1
5	Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11 Clinical Cancer Research ·Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman, Jennifer Sun, Jenny Nater, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, Tan Trinh, Mike Mattie, Frank Neumann, Jenny Kim, Christina To, Simone Filosto, Ran Reshef	2023	6
6	Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy Cancer Immunology Research ·Jack Pengfei Tang, Cole W. Peters, Crystal Quiros, Xiaoyan Wang, Alexandra M. Klomhaus, Reiko Yamada, John M. Timmerman, Theodore B. Moore, Theodore S. Nowicki	2022	19
7	89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model Molecular Cancer Therapeutics ·Kirstin A. Zettlitz, Felix B. Salazar, Reiko Yamada, K. Ryan Trinh, Alex Vasuthasawat, John M. Timmerman, Sherie L. Morrison, Anna M. Wu	2022	3
8	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) Journal of Translational Medicine ·Paolo A. Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Jérôme Galon, Samir N. Khleif, Tomas Kirchhoff, Jennifer L. McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Janis M. Taube, John M. Timmerman, Bernard A. Fox, Patrick Hwu, Igor Puzanov	2021	3
9	Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) Journal of Translational Medicine ·Paolo A. Ascierto, Lisa H. Butterfield, Kirk A. Campbell, Bruno Daniele, Michael Dougan, Leisha A. Emens, Silvia C. Formenti, Filip Jankú, Samir N. Khleif, Tomas Kirchhoff, Alessandro Morabito, Yana G. Najjar, Paul Nathan, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Bradley I. Reinfeld, Heath D. Skinner, John M. Timmerman, Igor Puzanov	2021	2
10	The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 Journal for ImmunoTherapy of Cancer ·Paolo A. Ascierto, Carlo Bifulco, Jerome Galon, Claus Garbe, Samir N. Khleif, Jennifer L. McQuade, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sergio A. Quezada, Hussein A. Tawbi, John M. Timmerman, Giorgio Trinchieri, Lisa H. Butterfield, Igor Puzanov	2020	2
11	Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplantation ·Sanaz N. Ghafouri, John M. Timmerman, Sarah M. Larson, Monica Mead	2020	35
12	An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma Cancer Research ·Shili Xu, Tianyuan Zhou, Hanna M. Doh, K. Ryan Trinh, Art Catapang, Jason T. Lee, Daniel Braas, Nicholas Bayley, Reiko Yamada, Alex Vasuthasawat, Joshua Sasine, John M. Timmerman, Sarah M. Larson, Youngsoo Kim, A. Robert MacLeod, Sherie L. Morrison, Harvey R. Herschman	2019	44
13	In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells Blood ·Alex Vasuthasawat, Reiko Yamada, Kham R. Trinh, Neiki Rokni, Sherie L. Morrison, John M. Timmerman	2019	1
14	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell Hit paper breakdown →	2018	455
15	Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells Blood ·Hyung C. Suh, Katherine Pohl, Christina M. Termini, Jenny Kan, John M. Timmerman, Dennis J. Slamon, John P. Chute	2018	13
16	Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety Seminars in Oncology ·Patricia A. Young, Sherie L. Morrison, John M. Timmerman	2014	53
17	A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders Clinical Cancer Research ·John M. Timmerman, John C. Byrd, David Andorsky, Reiko Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel	2012	53
18	Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells Clinical Cancer Research ·David Andorsky, Reiko Yamada, Jonathan Said, Geraldine S. Pinkus, David J. Betting, John M. Timmerman	2011	267
19	Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma Clinical Cancer Research ·Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, Donna Fernando, Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman	2009	263
20	T cell antigen receptor vaccines for active immunotherapy of T cell malignancies The FASEB Journal ·Carmen P. Wong, Craig Okada, John M. Timmerman, Dan W. Denney, Ronald Levy	1998	1

About John M. Timmerman

John M. Timmerman is a scholar working on Pathology and Forensic Medicine, Oncology, Immunology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 108 papers that have together received 5.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (69 papers), CAR-T cell therapy research (66 papers), Cancer Immunotherapy and Biomarkers (36 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Chronic Lymphocytic Leukemia Research (11 papers), Immunotherapy and Immune Responses (11 papers), Biosimilars and Bioanalytical Methods (10 papers) and Immune Cell Function and Interaction (9 papers). The work is most often cited by research in Oncology (4.3k citations), Pathology and Forensic Medicine (2.2k citations), Immunology (2.6k citations), Genetics (717 citations) and Neurology (523 citations). John M. Timmerman has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Stephen M. Ansell, Philippe Armand, Margaret A. Shipp, Scott J. Rodig, Alexander M. Lesokhin, Li Zhu, Azra H. Ligon, Ivan Borrello, Martin Gutierrez and Bjoern Chapuy. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, Hematological Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact